SIGNATOPE
SIGNATOPE GmbH is a biotech company founded in 2016 in Reutlingen, Germany, specializing in developing innovative protein-assays and analytical services for pharmaceutical and chemical industries. They focus on creating assays for detecting and quantifying biomarkers related to organ damage and drug interactions, utilizing advanced mass spectrometry and immunoassay technologies. The company is committed to advancing biomarker research and improving drug safety and efficacy.
Industries
Nr. of Employees
small (1-50)
SIGNATOPE
Products
Terminal-sequence-recognizing antibody collection (~6,000 protein targets)
A reagent collection of monoclonal antibodies targeting tetramer peptide termini adjacent to protease cleavage sites, enabling capture of peptides from thousands of proteins for targeted mass spectrometric assays.
Targeted immunoaffinity LC-MS/MS assay panels (examples: CYPs and drug transporters)
Preconfigured targeted mass spectrometry-based immunoassay panels for direct quantification of drug-metabolizing enzymes and transport proteins in tissues and cell lysates.
Terminal-sequence-recognizing antibody collection (~6,000 protein targets)
A reagent collection of monoclonal antibodies targeting tetramer peptide termini adjacent to protease cleavage sites, enabling capture of peptides from thousands of proteins for targeted mass spectrometric assays.
Targeted immunoaffinity LC-MS/MS assay panels (examples: CYPs and drug transporters)
Preconfigured targeted mass spectrometry-based immunoassay panels for direct quantification of drug-metabolizing enzymes and transport proteins in tissues and cell lysates.
Services
Custom assay development and validation (mass spectrometry-based immunoassays)
Development, optimization and analytical validation of targeted immunoaffinity–mass spectrometry assays for detection and quantification of protein biomarkers in blood, urine and tissue.
Screening for matching terminal-sequence antibodies
In-silico and reagent matching service using Uniprot IDs or FASTA sequences to identify antibodies that bind conserved tetramer peptide termini, with a stated response turnaround.
Contract analytical testing for biomarker quantification
Analytical laboratory services to measure and report biomarker concentrations using targeted proteomics workflows for industry and consortium projects.
Custom assay development and validation (mass spectrometry-based immunoassays)
Development, optimization and analytical validation of targeted immunoaffinity–mass spectrometry assays for detection and quantification of protein biomarkers in blood, urine and tissue.
Screening for matching terminal-sequence antibodies
In-silico and reagent matching service using Uniprot IDs or FASTA sequences to identify antibodies that bind conserved tetramer peptide termini, with a stated response turnaround.
Contract analytical testing for biomarker quantification
Analytical laboratory services to measure and report biomarker concentrations using targeted proteomics workflows for industry and consortium projects.
Expertise Areas
- Targeted mass spectrometry-based immunoassays
- Biomarker assay development and validation
- Immunoaffinity enrichment for proteomics
- Cross-species biomarker assay design
Key Technologies
- Immunoaffinity enrichment
- LC-MS/MS
- Immuno-MRM
- Immuno‑MALDI